Biotech company asks shareholders to dilute stock by 951% to hoard illiquid crypto token instead of funding its own drug
Enlivex, a Nasdaq-listed biotechnology company, is asking shareholders to authorize up to $800 million of financing tied to the RAIN crypto token. The construction might enhance its share rely by as a lot as 951%.
Despite Enlivex’s biotech enterprise, the financing is primarily a crypto-treasury transaction. RAIN delivered at closing would go to the company’s treasury wallets, whereas considerably all money or stablecoin proceeds are earmarked to purchase the token or assist different treasury functions, transaction prices, and debt. Only up to 5% of remaining USD proceeds might fund Allocetra.
Shareholder approval is required for an preliminary $400 million placement and the utmost securities accessible below a separate, company-controlled $400 million possibility. The first tranche alone might equal roughly 4 to 5 occasions Enlivex’s newest disclosed shares excellent.
Enlivex mentioned in a Form 6-K that it might use commercially cheap efforts to name and maintain the assembly inside 60 days of its July 27 settlement.
Under the securities purchase agreement, the investor elected to pay within the RAIN token however can change that selection earlier than closing. RAIN consideration carries a $6 whole worth per ordinary-share equal, whereas USD, USDT, or USDC carries a $5 worth.
The public paperwork don’t clearly establish the customer. The 6-Okay calls it Rain Foundation, whereas the settlement defines Token Factor Foundation because the lead investor and leaves the general public purchaser signature block clean. The filings don’t set up whether or not the 2 names refer to the identical entity.
Dilution is determined by the cost methodology
If the primary tranche is paid solely in RAIN, it represents about 66.7 million bizarre shares or underlying pre-funded-warrant shares. Payment solely in money or stablecoins would characterize 80 million. Enlivex mentioned in a July 7 submitting that its 1-for-15 reverse split would cut back issued and excellent shares to roughly 16.83 million.
The preliminary issuance subsequently equals about 396% of that baseline on the RAIN worth or 475% on the cash-like worth. On a share-equivalent foundation, present holders would account for roughly 20.2% or 17.4% of the enlarged whole, respectively.
The comparability makes use of issued and excellent shares as a result of the filings present no present totally diluted rely. Enlivex’s newest detailed possibility and warrant desk is dated Dec. 31, 2025, whereas a later Lind financing permits variable share issuance, so these historic figures can’t safely be mixed with the July rely.
Full use of the non-compulsory second tranche below one cost methodology would carry whole new share equivalents to about 133.3 million on the RAIN worth or 160 million on the cash-like worth. That is roughly 792% or 951% of the present excellent baseline, leaving current holders at about 11.2% or 9.5% of the ensuing share-equivalent whole.
Pre-funded warrants don’t take away that overhang. They are instantly exercisable and don’t expire, though beneficial-ownership limits can delay train.
The vote should cowl securities for each the preliminary closing and the utmost put below Israeli regulation and Nasdaq guidelines. After closing, Enlivex might compel the lead investor to purchase up to one other $400 million of shares or pre-funded warrants over so long as 36 months. The investor can’t demand that second buy, and Enlivex will not be assured the extra proceeds.
The proceeds favor RAIN over Allocetra
Substantially all internet proceeds paid in USD, USDT, or USDC are earmarked for buying RAIN, different treasury functions, transaction prices, and excellent debt. Only up to 5% of USD internet proceeds remaining after charges, bills, and debt might fund Allocetra. RAIN delivered at closing goes to the company treasury wallets.
RAIN amount will likely be set from CoinMarketCap’s common closing worth over the 5 enterprise days earlier than closing. That calculation doesn’t set up realizable money worth. CryptoSlate’s point-in-time RAIN market page confirmed about $29.88 million in 24-hour reported quantity, making $400 million roughly 13.4 occasions at some point’s turnover. Reported quantity will not be executable liquidity.
The put up Biotech company asks shareholders to dilute stock by 951% to hoard illiquid crypto token instead of funding its own drug appeared first on CryptoSlate.
